MedPath

Guanfacine

Generic Name
Guanfacine
Brand Names
Intuniv, Tenex
Drug Type
Small Molecule
Chemical Formula
C9H9Cl2N3O
CAS Number
29110-47-2
Unique Ingredient Identifier
30OMY4G3MK

Overview

Guanfacine, or BS 100-141, is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974. Guanfacine was granted FDA approval on 27 October 1986.

Background

Guanfacine, or BS 100-141, is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974. Guanfacine was granted FDA approval on 27 October 1986.

Indication

Guanfacine is indicated alone or as an adjunct with stimulants to treat ADHD.

Associated Conditions

  • Attention Deficit Hyperactivity Disorder (ADHD)
  • Gilles de la Tourette's Syndrome
  • Hypertension
  • Migraine

FDA Approved Products

Guanfacine
Manufacturer:Ajanta Pharma USA Inc.
Route:ORAL
Strength:2 mg in 1 1
Approved: 2022/09/07
NDC:27241-243
Guanfacine
Manufacturer:Ajanta Pharma USA Inc.
Route:ORAL
Strength:1 mg in 1 1
Approved: 2022/09/07
NDC:27241-242
Guanfacine
Manufacturer:Bryant Ranch Prepack
Route:ORAL
Strength:4 mg in 1 1
Approved: 2023/12/07
NDC:72162-1801
Guanfacine Hydrochloride
Manufacturer:REMEDYREPACK INC.
Route:ORAL
Strength:2 mg in 1 1
Approved: 2024/01/15
NDC:70518-3516
Guanfacine
Manufacturer:Slate Run Pharmaceuticals, LLC
Route:ORAL
Strength:2 mg in 1 1
Approved: 2024/01/21
NDC:70436-040

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath